EUPRAXIA PHARMACEUTICALS INC.

EUPRAXIA PHARMACEUTICALS INC. (NASDAQ:EPRX) is a publicly traded company in the Life Sciences sector. Wiseek monitors EPRX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

• Eupraxia Pharmaceuticals Reports Strong Histological Improvements in EoE Trial (2026-05-06)
• Eupraxia Pharmaceuticals Reports Strong EREFS Data for EP-104GI in EoE RESOLVE Trial (2026-05-05)
• Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer (2026-05-01)
• Eupraxia to Present Positive EP-104GI EoE Data at Digestive Disease Week, Host KOL Investor Event (2026-04-22)
• Eupraxia Reports Positive 36-Week Data for EP-104GI in EoE Trial, Showing Sustained Efficacy & Safety (2026-04-21)

Insider Transactions

EPRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.